Ainos Bilan de santé

Santé financière contrôle des critères 3/6

Ainos possède un total de capitaux propres de $24.4M et une dette totale de $5.7M, ce qui porte son ratio d'endettement à 23.3%. Son actif total et son passif total sont $31.8M et de $7.4M.

Informations clés

23.3%

Ratio d'endettement

US$5.69m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$1.89m
Fonds propres	US$24.45m
Total du passif	US$7.39m
Total des actifs	US$31.84m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de FZX ( $2.5M ) dépassent ses passifs à court terme ( $1.3M ).

Passif à long terme: Les actifs à court terme de FZX ( $2.5M ) ne couvrent pas ses passifs à long terme ( $6.1M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de FZX ( 15.6% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de FZX a été réduit de 70.3% à 23.3% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: FZX dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: FZX dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 37.2 % chaque année

Ainos Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Recent updates

Ainos, Inc. Announces Institutional Review Board Approval for Sjögren’S Syndrome Clinical Study

Ainos, Inc. Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for HIV-Oral Warts Clinical Trial

Ainos, Inc. Receives IRB Approval from National Taiwan University Hospital for Hiv-Oral Warts Clinical Trial, Highlighting Value of Fda-Designated Orphan Drug Veldona

Ainos Announces Plan to Initiate Taiwan Clinical Study for Veldona as Potential Treatment of Oral Warts in HIV-Positive Patients

Ainos, Inc. Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Ainos, Inc., Annual General Meeting, Sep 27, 2024

Ainos, Inc Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Ainos Receives a Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022)

Less than half of directors are independent

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target

Ainos, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022)

Less than half of directors are independent

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines